GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Cyclically Adjusted Revenue per Share

Macrogenics (FRA:M55) Cyclically Adjusted Revenue per Share : €2.10 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Macrogenics's adjusted revenue per share for the three months ended in Mar. 2025 was €0.194. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.10 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Macrogenics's average Cyclically Adjusted Revenue Growth Rate was -6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-22), Macrogenics's current stock price is €1.351. Macrogenics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €2.10. Macrogenics's Cyclically Adjusted PS Ratio of today is 0.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Macrogenics was 7.59. The lowest was 0.45. And the median was 1.84.


Macrogenics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Macrogenics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Cyclically Adjusted Revenue per Share Chart

Macrogenics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.42 2.34 2.43

Macrogenics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.22 2.21 2.43 2.10

Competitive Comparison of Macrogenics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Macrogenics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's Cyclically Adjusted PS Ratio falls into.


;
;

Macrogenics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Macrogenics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.194/134.9266*134.9266
=0.194

Current CPI (Mar. 2025) = 134.9266.

Macrogenics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.166 100.684 0.222
201509 0.392 100.392 0.527
201512 0.251 99.792 0.339
201603 0.049 100.470 0.066
201606 1.940 101.688 2.574
201609 0.052 101.861 0.069
201612 0.258 101.863 0.342
201703 0.034 102.862 0.045
201706 0.027 103.349 0.035
201709 0.025 104.136 0.032
201712 3.488 104.011 4.525
201803 0.099 105.290 0.127
201806 0.377 106.317 0.478
201809 0.418 106.507 0.530
201812 0.311 105.998 0.396
201903 0.184 107.251 0.231
201906 0.181 108.070 0.226
201909 0.334 108.329 0.416
201912 0.452 108.420 0.563
202003 0.239 108.902 0.296
202006 0.278 108.767 0.345
202009 0.271 109.815 0.333
202012 0.756 109.897 0.928
202103 0.236 111.754 0.285
202106 0.425 114.631 0.500
202109 0.218 115.734 0.254
202112 0.178 117.630 0.204
202203 0.158 121.301 0.176
202206 0.401 125.017 0.433
202209 0.686 125.227 0.739
202212 1.091 125.222 1.176
202303 0.370 127.348 0.392
202306 0.195 128.729 0.204
202309 0.157 129.860 0.163
202312 0.135 129.419 0.141
202403 0.134 131.776 0.137
202406 0.160 132.554 0.163
202409 1.587 133.029 1.610
202412 0.270 133.157 0.274
202503 0.194 134.927 0.194

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Macrogenics  (FRA:M55) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Macrogenics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.351/2.10
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Macrogenics was 7.59. The lowest was 0.45. And the median was 1.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Macrogenics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Macrogenics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics Headlines

No Headlines